# Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

> **NCT02465437** · PHASE2 · TERMINATED · sponsor: **Corbus Pharmaceuticals Inc.** · enrollment: 42 (actual)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis

## Interventions

- **DRUG:** JBT-101
- **DRUG:** Placebo
- **DRUG:** Part B Open-Label Extension

## Key facts

- **NCT ID:** NCT02465437
- **Lead sponsor:** Corbus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2016-10
- **Final completion:** 2020-12-11
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Sponsor terminated open-label extension
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465437, "Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02465437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*